Chengdu Easton Biopharmaceuticals Co., Ltd

Chengdu Shibeikang Biomedical Technology Co., Ltd.

Chengdu Easton Pharmaceutical Co., Ltd.

Zhejiang Yatai Pharmaceutical Co., Ltd.

Guodong Cen

Ying Wang

Long Huang

Yongzhe Xiang

Jian Ming Liu

Ning Zhou

Shaojun Tan

Maoting Yang

Jibing Zhang

Haitao Yang

Qing Dong

Yang Liu

Jian Liu

Jianguo Li

Hui Qiao

Qiangqiang Liu

Jianjing Jia

Disclosed in the present invention are a crystalline form B of a tetrahydrothienopyridine compound having a structure as represented by Compound I, a preparation method, a composition and an application thereof, for use in solving the problems in the prior art of lots of impurities, low content, bad crystalline form stability, and inability to form a drug. The crystalline form B uses Cu-Kα radiation, and X-ray powder diffraction expressed at a 2θ angle has characteristic peaks at 11.21±0.2°, 12.61±0.2°, 14.69±0.2°, 16.14±0.2°, 17.81±0.2°, 20.22±0.2°, and 22.10±0.2°. The crystalline form B of the present invention has few of impurities, good stability, good crystallinity, and reproducibility, and is suitable for industrial production. Moreover, the crystalline form B has an unexpectedly stronger anti-ADP-induced platelet aggregation effect and better fluidity.

Crystalline form B of tetrahydrothienopyridine compound, preparation method, composition and application thereof

A dibromobenzyl derivative with a structure shown as formula I, a stereoisomer or a pharmaceutically acceptable salt thereof and a preparation method and an application of the dibromobenzyl derivative are provided. The dibromobenzyl derivative or the stereoisomer thereof is superior in in-vivo pharmacokinetic stability and drug efficacy, and capable of being used for preparing respiratory drugs, in particular the apophlegmatic drugs.

Dibromobenzyl derivative, stereoisomer or salt thereof, and preparation method and application of dibromobenzyl derivative

Provided a complex of formula is [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3'-methyl-2&#x2032;-(pentanoyl {2&#x2033;-(tetrazol-5-ylate) biphenyl-4&#x2032;-ylmethyl}amino) butyrate].XCa.YNa.ZHO, wherein X=1-3, Y=12-16, Z=9-18, and 2X+Y=18, and represented by formula (I). Also disclosed are the method of preparing the complex and the method of treating chronic heart disease using a medicament comprising the complex. 

Complex of angiotensin receptor antagonist and neutral endopeptidase inhibitor

The present invention relates to the field of pharmaceutical chemistry, specifically to a class of compounds containing lactam and derivative thereof, and especially to a pyridine derivative as shown in general formula (I), preparation method and the use thereof as a Factor Xa inhibitor. The present invention further relates to the medical use of the compound and derivative thereof in preparation of anticoagulant drugs, particularly to the use in preparation of drugs for preventing or treating thrombosis or embolism. 

Pyridine derivative and medical use thereof

The present invention discloses a xanthine derivative having the structure of the following general formula (I) or a pharmaceutically acceptable salt thereof; further discloses a preparation method for the xanthine derivative or a pharmaceutically acceptable salt thereof; and further discloses the use of the xanthine derivative or a pharmaceutically acceptable salt thereof. Through experiments of DPP-IV activity inhibition experiments in vitro, impact on glucose tolerance in normal mice and impact on blood glucose in spontaneous diabetic mice, it proves that the compounds and pharmaceutically acceptable salts thereof show good DPP-IV inhibition activity, can be applied to prepare medicines for treating dipeptidyl peptidase IV-related diseases, and more particularly, can be applied to the use of medicines for treating type II diabetes or diseases of abnormal glucose tolerance. 

Xanthine derivative

Growing community of inventors

Chengdu, China

Guodong Cen